Marinus Pharmaceuticals, Inc.

MRNS

US56854Q2003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-19 pm EDT			5-day change	1st Jan Change
1.600 ^USD	+5.96%		+15.11%	-85.28%

Aug. 14	Ladenburg Thalmann Downgrades Marinus Pharmaceuticals to Neutral From Buy	MT
Aug. 13	Marinus Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 13, 2024

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index

July 30, 2024

Latest news about Marinus Pharmaceuticals, Inc.

Ladenburg Thalmann Downgrades Marinus Pharmaceuticals to Neutral From Buy	Aug. 14	MT
Marinus Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 13, 2024	Aug. 13
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 13	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q2 Revenue $8.1M, vs. Street Est of $9.5M	Aug. 13	MT
Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024	Aug. 13	CI
Marinus Pharmaceuticals' Ganaxolone Approved in China for Epileptic Seizures	Jul. 18	MT
Marinus Pharmaceuticals Announces Ganaxolone Approves in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder	Jul. 18	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2500 Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000 Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000 Growth Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Dynamic Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Completeness Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2500 Growth Index	Jun. 30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index	Jun. 23	CI
Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17	MT
Top Premarket Decliners	Jun. 17	MT
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study	Jun. 17	MT
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus	Jun. 17	CI
Marinus Pharmaceuticals, Inc. Enter into an Amendment to Its Previously Disclosed Credit Agreement with Oaktree Fund Administration, Llc	Jun. 06	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT

Chart Marinus Pharmaceuticals, Inc.

Duration

Period

More charts

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Employees

166

Sector

Pharmaceuticals

Calendar

09:00am - Investor and Analyst Day

More about the company